[Evaluation of the use of highly sensitive methods of determining alpha-fetoprotein for the diagnosis of hepatocellular cancer and teratoblastoma].

Abelev Gi, Tsvetkov Vs, Biriulina Ti, El'gort Da, Olovnikov Am

PubMed · 1971 · 15 citations · 0 references

Concepts

Abstract

Aggregate hemagglutination (AHA) and immunoautoradiography (IAR) tests for alpha fetoprotein (AFP) were evaluated by determining AFP levels of sera of patients with malignant tumors nontumorous diseases and normal donors. 22/48 patients with primary liver cancer had detectable amounts of AFP in sera and 15/22 patients with cancer of the testis and ovary had detectable AFP levels. AFP in the sera of these patients was not detectable by precipitation in agar. In 12% of cases AFP was found in infectious hepatitis and the appearance of AFP was reversible compared with cancer of the liver and teratoblastoma. AFP was found in 2% (2/108 cases) of nontumorous liver diseases. In metastatic liver cancer AFP was measured in 13% (3/23 cases); and in tumors of other localization AFP was detectable in 1% (1/110) cases. AFP was not revealed in normal donor sera but it was demonstrated in 98% of pregnant women after the 15th week of gestation. Though the use of both AHA and IAR tests increased the percentage of serologically identified hepatocellular carcinoma and teratoblastoma their use simultaneously raised the incidence of false-positive results. The difference in dynamics of AFP in tumors and infectious hepatitis may serve as a basis for differential diagnosis of these diseases. For example whereas AFP levels steadily increased in hepatoma or teratoblastoma with the progress of the disease in Botkins disease AFP levels rapidly rose and then dropped off as fast as they were growing. Appearance of AFP in this disease is probably due to active regeneration of the liver. It is possible that similar regenerative processes are responsible for elevated AFP levels in isolated cases of mechanical jaundice hepatocholestitis and metastatis. Concomitant use of AHA and IAR methods for diagnosis of hepatoma and teratoblastoma is recommended.